
The FDA grants accelerated approval to neladalkib for pretreated ALK-positive lung cancer, showing how next-gen kinase inhibitors tackle drug resistance
Ashland
Cambridge Major Laboratories
Jost Chemicals
Pfizer CentreSource
Vetter Pharma International GmbH






